Lymphoma Coalition 2020 Global Patient Survey – Week 3 Update

Dear Members,

To date, we have received 3305 responses (patient and caregiver surveys combined) to the 2020 Global Patient Survey on Lymphomas & CLL. This week we have seen an increase in the number of groups who will receive a country report, and there are a number of others who are close.

Promoting the survey works and we encourage each group to participate. Keep reading to the end of this email for more information on marketing the survey, including information on what has been translated for your use.

See below for the survey count by member countries for patient respondents. Please remember caregivers have their own survey this year and these numbers are being tracked separately.  
 

COUNTRY SURVEYS COUNTRY SURVEYS
Algeria 1 Latvia 0
Argentina 56 Lithuania 26
Australia 111 Macedonia 0
Barbados 1 Mexico 3
Belgium 89 Morocco 9
Brazil 4 New Zealand 184
Bulgaria 42 Norway 3
Canada 259 Poland 0
China 2 Portugal 8
Colombia 1 Romania 1
Croatia 10 Russia 0
Czech Republic 1 Serbia 59
Denmark 8 Singapore 0
Finland 39 Slovakia 26
France 866 Slovenia 10
Germany 31 South Africa 4
Greece 3 Spain 4
Hong Kong 2 Sweden 147
Hungary 2 Switzerland 35
India 51 The Netherlands 51
Iraq 0 Turkey 1
Ireland 20 Ukraine 0
Israel 0 United Kingdom 179
Italy 153 United States 312
Japan 5 Uruguay 9
Korea 4 Venezuela 1

The highlighted countries have surpassed 100 respondents, and will receive a country report. 

Congratulations to Blodcancerförbundet in Sweden who have qualified for a country report for the first time with 147 patient respondents! Cheers to Australia, Italy and New Zealand, who have seen a substantial jump in survey responses this week. As well, both France Lymphome Espoir and SILLC have worked hard promoting the survey, resulting in the highest number of respondents we have ever had from France.

We have also tracked the survey completion counts by subtype from patient respondents:
 

SUBTYPE SURVEYS
Anaplastic large cell 17
Burkitts 34
CL 144
CLL/SLL 755
DLBCL (unspecified) 290
DLBCL (GCB) 22
DLBCL (ABC) 34
Extranodal Killer T-cell 0
FL 383
HL 412
MALT 40
Mantle cell 69
Peripheral T-cell 26
Transformed 37
WM 400

The highlighted subtypes have surpassed 100 respondents, and will have a subtype report. ​ 

Thank you to everyone who has already shared the 2020 Global Patient Survey. For those that have not done so, please share the link with your membership, healthcare community and social media. The marketing materials can be found on the members side of the LC website. The materials have all been translated into the same 19 languages that the survey is offered in. CLICK HERE to access them. Your login is required. If you need help with your username and password, please contact marketing@lymphomacoalition.org

Here's what you can do to help us reach our goal:

  • Host the information on your website. 
  • Send an email to your membership, sponsors and other partners encouraging them to take the survey and pass the message along.
  • Share with your followers on social media.
  • Here is the link to the survey from the LC website
  • Here is the link directly to the survey (if you share this link, the survey will automatically show in the language that the respondent’s internet browser uses if it is one of the translated languages).

All your efforts to help promote participation in the 2020 Global Patient Survey are greatly appreciated.

Reminder - countries with 100+ respondents (from patients) will receive a specialised by country report. 

Together, we will ensure patients are given the opportunity to share their experience and help shape the global lymphoma landscape.
 
Warm regards,


Lorna